ArticleEuropean radiology2005
Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI.
Article in European radiology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group.Cancer imaging : the official publication of the International Cancer Imaging Society · 2012Guideline
- Predicting the progression-free survival of gastrointestinal stromal tumors after imatinib therapy through multi-sequence magnetic resonance imaging.Abdominal radiology (New York) · 2024Article
- Utility of noncontrast MRI in the detection and risk grading of gastrointestinal stromal tumor: a comparison with contrast-enhanced CT.Quantitative imaging in medicine and surgery · 2021Article
- Gastrointestinal Stromal Tumors of the Distal Gastrointestinal Tract.Clinics in colon and rectal surgery · 2018Review
- MRI in predicting the response of gastrointestinal stromal tumor to targeted therapy: a patient-based multi-parameter study.BMC cancer · 2018Article
- Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review.Clinical and translational imaging · 2017Review
- Gastrointestinal imaging-practical magnetic resonance imaging approach.World journal of radiology · 2014Review
- CT scan is not everything in the evaluation of a patient with gastrointestinal tumors (GIST) under imatinib therapy.Pathology oncology research : POR · 2012Article
- [Imaging of soft tissue sarcomas: standard approaches and new strategies].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2009Review
- [New imaging strategies for monitoring molecular pharmacotherapy of GIST].Der Radiologe · 2008Review
- The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction.World journal of surgical oncology · 2008Article
- Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate.World journal of gastroenterology · 2008Article
- Prognostic factors affecting survival after surgical resection of gastrointestinal stromal tumours: a two-unit experience over 10 years.World journal of surgical oncology · 2006Article
- [Surgical considerations for gastrointestinal stroma tumor].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Typical MRI findings for gastro-intestinal stromal tumours (GIST) under treatment with imatinib were evaluated. MRI was performed in 45 patients (25 responders, 20 non-responders) with metastatic or locally advanced, unresectable GIST. Target lesions were selected and re-evaluated after 2, 4, and 6 months of therapy with imatinib. The target tumour response (TTR) was classified according to RECIST criteria. TTR, signal intensity in the centre and border of the lesion and the presence and the extension of a hypervascular rim were analysed. The mean diameter of the marker lesions decreased significantly (P<0.001) from 7.1+/-2.6 cm to 5.9+/-2.3 cm after 6 months. Accuracy of RECIST criteria was 51%, 69% and 73% on MRI 2, 4 and 6 months for response assessment. In addition, responders had higher signal-to-noise ratios on T2-w images after 2 months (P<0.05) and a decrease of vascularised areas in the lesion 4 and 6 months after treatment (each P<0.01), when compared with non-responders. Beyond the size measurement for response assessment, MRI provides additional information of tumour response using SI of T2-w images and quantification of vascularised areas of GIST manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.